@article {Naik2021.06.17.21259066, author = {Shivdas Rajaram Naik and Swasthi S Kumar and Ankit Mittal and Satish Swain and Sanjay Ranjan and Manish Soneja and Sanjeev Sinha and Neeraj Nischal and Pankaj Jorwal and Pradeep Chaturvedi and Naveet Wig}, title = {Seroprevalence of COVID-19 in HIV Population}, elocation-id = {2021.06.17.21259066}, year = {2021}, doi = {10.1101/2021.06.17.21259066}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Seroprevalence helps us to estimate the exact prevalence of a disease in a population. Although the world has been battling this pandemic for more than a year now, we still do not know about the burden of this disease in people living with HIV/AIDS (PLHA). Seroprevalence data in this population subset is scarce in most parts of the world, including India. The current study aimed to estimate the seroprevalence of anti-SARS-CoV-2 IgG antibody among PLHA.Aim To determine the seroprevalence of SARS-CoV-2 antibodies in PLHA.Method This was a cross-sectional study conducted at a tertiary care hospital in North India. We recruited HIV positive patients following at the ART centre of the institute. Anti-SARS-CoV-2 IgG antibody levels targeting recombinant spike receptor-binding domain (RBD) protein of SARS CoV-2 were estimated in serum sample by the chemiluminescent immunoassay method.Results A total of 164 patients were recruited in the study with a mean age ({\textpm}SD) of 41.2 ({\textpm}15.4) years, of which 55\% were male. Positive serology against SARS CoV-2 was detected in 14\% patients (95\% CI: 9.1-20.3\%).Conclusion The seroprevalence of COVID-19 infection in PLHA was lower than the general population in the same region, which ranged from 23.48\% to 28.3\% around the study period.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was cleared by the institutional ethics committee of AIIMS, New Delhi (IECPG/439/8/2020)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is saved with the first author and can be made available if requested. but this is not stored on any URLs}, URL = {https://www.medrxiv.org/content/early/2021/06/24/2021.06.17.21259066}, eprint = {https://www.medrxiv.org/content/early/2021/06/24/2021.06.17.21259066.full.pdf}, journal = {medRxiv} }